Physician profile

Jane L Liesveld

Hematology (Internal Medicine) · Rochester, NY

NPI 1851319610

$43,330.69

in general payments reported to CMS, 2019-2025

23 companies · $3,363 in 2025

The $3,363 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).

See the full distribution for Hematology (Internal Medicine)

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$20,672.50
Travel and Lodging$1,123.64
Food and Beverage$626.05
Honoraria$600.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Servier Pharmaceuticals LLC $20,101.43 2022-2023
Merck Sharp & Dohme LLC $6,500.00 2019-2024
National Marrow Donor Program $5,000.00 2022-2025
Novartis Pharmaceuticals Corporation $2,762.50 2025
Blueprint Medicines Corporation $2,632.50 2021
Celgene Corporation $2,140.94 2019-2021
Daiichi Sankyo INC. $1,935.00 2022
Pharmacosmos Therapeutics INC. $1,500.00 2021
Jazz Pharmaceuticals INC. $596.74 2019-2024 Rylaze
Kite Pharma, INC. $111.58 2019
Biolinerx USA, INC. $50.00 2024 Aphexda

12 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$59,921.70 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jane L Liesveld

$43,330.69

in general payments reported 2019-2025

Years
2019-2025
Top company
Takeda Pharmaceuticals U.S.A., INC.
Context
The $3,363 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).

https://glasscript.com/doctor/985647/jane-l-liesveld

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.